litlas
Log inCreate account

Hans Wildiers

Active 2002–2025

168
Papers
25,702
Citations
84
h-index
159
i10-index

Citations

Citations per year for Hans Wildiers1986: 1 citations1992: 1 citations1999: 1 citations2003: 2 citations2004: 4 citations2005: 14 citations2006: 25 citations2007: 34 citations2008: 31 citations2009: 40 citations2010: 51 citations2011: 52 citations2012: 102 citations2013: 130 citations2014: 164 citations2015: 151 citations2016: 222 citations2017: 245 citations2018: 226 citations2019: 811 citations2020: 883 citations2021: 915 citations2022: 870 citations2023: 696 citations2024: 1,250 citations2025: 699 citations2026: 23 citations1987–1991: no citations, so these years are not shown1993–1998: no citations, so these years are not shown2000–2002: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,616 citing papers, 19.3% of this breakdownChina: 1,218 citing papers, 9% of this breakdownUnited Kingdom: 831 citing papers, 6.1% of this breakdownItaly: 785 citing papers, 5.8% of this breakdownFrance: 596 citing papers, 4.4% of this breakdownGermany: 589 citing papers, 4.4% of this breakdownSpain: 528 citing papers, 3.9% of this breakdownCanada: 479 citing papers, 3.5% of this breakdownBelgium: 470 citing papers, 3.5% of this breakdownNetherlands: 454 citing papers, 3.4% of this breakdownAustralia: 425 citing papers, 3.1% of this breakdownJapan: 300 citing papers, 2.2% of this breakdown
0%19.3%Other 31.4%

Institutions

Fields

  • Medicine63.6%
  • Biochemistry, Genetics and Molecular Biology28.4%
  • Immunology and Microbiology2.5%
  • Engineering0.9%
  • Computer Science0.8%
  • Materials Science0.6%
  • Other3.2%

Topics

  • HER2/EGFR in Cancer Research5.5%
  • Breast Cancer Treatment Studies5%
  • Advanced Breast Cancer Therapies4.3%
  • Frailty in Older Adults3%
  • Cancer Immunotherapy and Biomarkers2.6%
  • Cancer Treatment and Pharmacology2.4%
  • Other77.2%

Coauthors

All papers

Open in search
  1. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer

    Authors: Ayse Bassez, Hanne Vos, Laurien Van Dyck, Giuseppe Floris, Ingrid Arijs, Christine Desmedt, Bram Boeckx, Marlies Vanden Bempt, Ines Nevelsteen, Kathleen Lambein, Kevin Punie, Patrick Neven, Abhishek D. Garg, Hans Wildiers, Junbin Qian, Ann Smeets, Diether Lambrechts - Nature Medicine 2021 cited by 915

  2. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

    Authors: Aditya Bardia, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H. Barrios, Joyce O’Shaughnessy, Hans Wildiers, Jean‐Yves Pierga, Qingyuan Zhang, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Seock‐Ah Im, Christelle Lévy, William Jacot, Natasha Begbie, Jun Ke, Gargi Patel, Giuseppe Curigliano - New England Journal of Medicine 2024 cited by 393

  3. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

    Authors: Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng, Ming‐Shen Dai, Shang-Wen Chen, Sara A. Hurvitz, Sung‐Bae Kim, Beverly Moy, Suzette Delaloge, William J. Gradishar, Norikazu Masuda, Markéta Palácová, Maureen Trudeau, Johanna Mattson, Yoon Sim Yap, Ming‐Feng Hou, Michelino De Laurentiis, Yu‐Min Yeh, Hong‐Tai Chang, Thomas Yau, Hans Wildiers, Barbara Haley, Daniele Fagnani, Yen‐Shen Lu, John Crown, Johnson Lin, Masato Takahashi, Toshimi Takano, Miki Yamaguchi, Takaaki Fujii, Bin Yao, Judith D. Bebchuk, Kiana Keyvanjah, Richard Bryce, Adam Brufsky, for the NALA Investigators - Journal of Clinical Oncology 2020 cited by 609

  4. A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling

    Authors: Patricia Altea‐Manzano, Ginevra Doglioni, Yawen Liu, Alejandro M. Cuadros, Emma Nolan, Juan Fernández-García, Qi Wu, Mélanie Planque, Kathrin Laue, Florencia Cidre‐Aranaz, Xiao‐Zheng Liu, Oskar Marín-Béjar, Joke Van Elsen, Ines Vermeire, Dorien Broekaert, Sofie Demeyer, Xander Spotbeen, Jakub Idkowiak, Aurélie Montagne, Margherita Demicco, H. Furkan Alkan, Nick Rabas, Carla Riera‐Domingo, François Richard, Tatjana Geukens, Maxim De Schepper, Sophia Leduc, Sigrid Hatse, Yentl Lambrechts, Emily Kay, Sérgio Lilla, Alisa Alekseenko, Vincent Geldhof, Bram Boeckx, Celia de la Calle Arregui, Giuseppe Floris, Johannes V. Swinnen, Jean‐Christophe Marine, Diether Lambrechts, Vicent Pelechano, Massimiliano Mazzone, Sara Zanivan, Jan Cools, Hans Wildiers, Véronique Baud, Thomas G. P. Grünewald, Uri Ben‐David, Christine Desmedt, Ilaria Malanchi, Sarah‐Maria Fendt - Nature Cancer 2023 cited by 142

  5. International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer

    Authors: Hans Wildiers, Pieter Heeren, Martine Puts, Eva Topinková, Maryska L.G. Janssen‐Heijnen, Martine Extermann, Claire Falandry, Andrew Artz, Étienne Brain, Giuseppe Colloca, Johan Flamaing, Theodora Karnakis, Cindy Kenis, Riccardo A. Audisio, Supriya G. Mohile, Lazzaro Repetto, Barbara L. van Leeuwen, Koen Milisen, Arti Hurria - Journal of Clinical Oncology 2014 cited by 1,799

  6. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

    Authors: Sara A. Hurvitz, Miguel Martín, W. Fraser Symmans, Kyung Hae Jung, Chiun‐Sheng Huang, Alastair M. Thompson, Nadia Harbeck, Vicente Valero, Daniil Stroyakovskiy, Hans Wildiers, Mario Campone, Jean-François Boileau, Matthias W. Beckmann, Karen Afenjar, Rodrigo Fresco, Hans‐Joachim Helms, Jin Xu, Yvonne G. Lin, Joseph A. Sparano, Dennis J. Slamon - The Lancet Oncology 2017 cited by 529

  7. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

    Authors: Giuseppe Curigliano, Harold J. Burstein, Michael Gnant, Sibylle Loibl, David Cameron, Meredith M. Regan, Carsten Denkert, Philip Poortmans, William P. Weber, Beat Thürlimann, Stefan Aebi, Meteb Al‐Foheidi, Fabrice André, Mykola Anikusko, R. Badwe, A.V. Barrio, Carlos H. Barrios, Jonas Bergh, Hervé Bonnefoi, Daniela Morales, Sara Y. Brucker, Harold J. Burstein, Carlos Caldas, David Cameron, F. Cardoso, Maria João Cardoso, L.A Carey, Stephen Chia, Charlotte E. Coles, J. Cortes, Giuseppe Curigliano, Jana de Boniface, Suzette Delaloge, A. DeMichele, Carsten Denkert, Gerd Fastner, Florian Fitzal, Prudence A. Francis, H Gamal, Oreste ­Gentilini, Michael Gnant, William J. Gradishar, B. Gulluoglu, Nadia Harbeck, Jörg Heil, Chien Shiun Huang, Jens Huober, Zeping Jiang, Orit Kaidar‐Person, Marleen Kok, Eun‐So Lee, Sherene Loi, S. Loibl, Miguel Martín, Icro Meattini, Monica Morrow, A. H. Partridge, Frédérique Penault‐Llorca, Martine Piccart, Lori J. Pierce, Philip Poortmans, Meredith M. Regan, J. S. Reis-Filho, Isabel T. Rubio, Hope S. Rugo, Emiel J. Rutgers, Cristina Saura, Elżbieta Senkus, Zhi-Ming Shao, Christian F. Singer, Tanja Španič, Beat Thuerlimann, Masakazu Toi, Sara M. Tolaney, Nicholas C. Turner, Andrew Tutt, M.-J. Vrancken Peeters, Toru Watanabe, William P. Weber, Hans Wildiers, B. Xu - Annals of Oncology 2023 cited by 221

  8. Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast

    Authors: Vincent Geldhof, Laura de Rooij, Liliana Sokol, Jacob Amersfoort, Maxim De Schepper, Kateřina Rohlenová, Griet Hoste, Adriaan Vanderstichele, Anne-Marie Delsupehe, Edoardo Isnaldi, Naima Dai, Federico Taverna, Shawez Khan, Anh-Co Khanh Truong, Laure-Anne Teuwen, François Richard, Lucas Treps, Ann Smeets, Ines Nevelsteen, Birgit Weynand, Stefan Vinckier, Luc Schoonjans, Joanna Kalucka, Christine Desmedt, Patrick Neven, Massimiliano Mazzone, Giuseppe Floris, Kevin Punie, Mieke Dewerchin, Guy Eelen, Hans Wildiers, Xuri Li, Yonglun Luo, Peter Carmeliet - Nature Communications 2022 cited by 160

  9. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

    Authors: Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortés, Véronique Dièras, Debra A. Patt, Hans Wildiers, Clifford A. Hudis, Joyce O’Shaughnessy, Esther Zamora, Denise A. Yardley, Martin Frenzel, Andrew Koustenis, José Baselga - Clinical Cancer Research 2017 cited by 683

  10. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    Authors: Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n, Patricia LoRusso, Jean-­Marc Ferrero, Tanja Badovinac-Črnjević, Silke Hoersch, Melanie C. Smitt, Hans Wildiers - The Lancet Oncology 2017 cited by 523

  11. Cancer and Aging: Two Tightly Interconnected Biological Processes

    Authors: Lieze Berben, Giuseppe Floris, Hans Wildiers, Sigrid Hatse - Cancers 2021 cited by 234

  12. Vascular Endothelial Growth Factor and Angiogenesis

    Authors: Ann Hoeben, Bart Landuyt, Martin Highley, Hans Wildiers, Allan T. van Oosterom, E. A. de Bruijn - Pharmacological Reviews 2004 cited by 1,833

  13. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).

    Authors: Giuseppe Curigliano, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H. Barrios, Joyce O’Shaughnessy, Hans Wildiers, Qingyuan Zhang, Seock‐Ah Im, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Christelle Lévy, William Jacot, Natasha Begbie, Jun Ke, Gargi Patel, Aditya Bardia - Journal of Clinical Oncology 2024 cited by 102

  14. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

    Authors: Philippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, Debora Fumagalli, Christos Sotiriou, Einav Nili Gal‐Yam, Mark E. Robson, Justin Ndozeng, Angelo Di Leo, Eva Ciruelos, Evandro de Azambuja, Giuseppe Viale, Elsemieke D. Scheepers, Giuseppe Curigliano, Judith M. Bliss, Jorge S. Reis‐Filho, Marco Colleoni, Marija Balić, Fátima Cardoso, Joan Albanell, Caroline Duhem, Sandrine Marréaud, Dario Romagnoli, Beatriz Rojas, Andrea Gombos, Hans Wildiers, Ángel Guerrero‐Zotano, Peter S Hall, Andrea Bonetti, Karolina Larsson, Martina Degiorgis, Silvia Khodaverdi, Richard Greil, Ásgerður Sverrisdóttir, Marta Paoli, Ethel Seyll, Sibylle Loibl, Barbro Linderholm, Gabriele Zoppoli, Nancy E. Davidson, Oskar T. Johannsson, Philippe L. Bédard, Sherene Loi, Susan Knox, David Cameron, Nadia Harbeck, Maite Lasa Montoya, Mariana Brandão, Andrea Vingiani, Carmela Caballero, Florentine Hilbers, Lucy Yates, Matteo Benelli, David Venet, Martine Piccart - Cancer Discovery 2021 cited by 177

  15. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

    Authors: Sara A. Hurvitz, Miguel Martín, Kyung Hae Jung, Chiun‐Sheng Huang, Nadia Harbeck, Vicente Valero, Daniil Stroyakovskiy, Hans Wildiers, Mario Campone, Jean-François Boileau, Peter A. Fasching, Karen Afenjar, Gonzalo Spera, Vanesa López-Valverde, Chunyan Song, Peter C. Trask, Thomas Boulet, Joseph A. Sparano, W. Fraser Symmans, Alastair M. Thompson, Dennis J. Slamon - Journal of Clinical Oncology 2019 cited by 248

  16. Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

    Authors: Hope S. Rugo, Peter Kabos, Julia Beck, Guy Jérusalem, Hans Wildiers, Elena Sevillano, Luis Paz‐Ares, Michael Chisamore, Sonya C. Chapman, Anwar M. Hossain, Yanyun Chen, Sara M. Tolaney - npj Breast Cancer 2022 cited by 84

  17. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

    Authors: Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n, Patricia LoRusso, Jean-­Marc Ferrero, Melanie C. Smitt, Ron Yu, Abraham C.F. Leung, Hans Wildiers - The Lancet Oncology 2014 cited by 716

  18. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer

    Authors: Karen Van Baelen, Tatjana Geukens, Marion Maetens, Vivianne C. G. Tjan‐Heijnen, Christopher J. Lord, Sabine C. Linn, François‐Clément Bidard, F. Richard, William Yang, Rebecca E. Steele, Stephen J. Pettitt, Chantal Van Ongeval, Maxim De Schepper, Edoardo Isnaldi, Ines Nevelsteen, Ann Smeets, Kevin Punie, Leonie Voorwerk, Hans Wildiers, Giuseppe Floris, Anne Vincent‐Salomon, Patrick W.B. Derksen, Patrick Neven, Elżbieta Senkus, Emma Sawyer, Marleen Kok, Christine Desmedt - Annals of Oncology 2022 cited by 144

  19. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

    Authors: Aditya Bardia, Komal Jhaveri, Seock‐Ah Im, Sònia Pernas, Michelino De Laurentiis, Shusen Wang, Noelia Martínez-Jáñez, Giuliano Borges, David W. Cescon, Masaya Hattori, Yen‐Shen Lu, Erika Hamilton, Qingyuan Zhang, Junji Tsurutani, Kevin Kalinsky, Pedro Emanuel Rubini Liedke, Lu Xu, Rick M. Fairhurst, Sabrina S. Khan, Neelima Denduluri, Hope S. Rugo, Binghe Xu, Barbara Pistilli, for the TROPION-Breast01 Investigators, Betiana Romitelli, Ernesto Korbenfeld, Cristian Buono, Arturo Barbero, Geronimo Rosselli, Sergio Daniele, Sandra Anabel Ostoich, Hans Wildiers, Kevin Punie, Joëlle Collignon, Guy Jérusalem, Andrea Gombos, Giuliano Borges, Pedro Emanuel Rubini Liedke, Marcelle Goldner Cesca, Patrícia Medeiros Milhomem Beato, Laura Testa, Hélio Pinczowski, Liane Rapatoni, Debora de Melo Gagliato Jardim, José Bines, David W. Cescon, Jamil Asselah, Andre Blais, Joanne Yu, Jennifer Friedmann, Cristiano Ferrario, Binghe Xu, Shusen Wang, Qingyuan Zhang, ZeFei Jiang, Zhongsheng Tong, Quchang Ouyang, Jingfen Wang, Tingjing Yao, Yongsheng Wang, Xiaojia Wang, Meili Sun, Hui Li, Shu Wang, Yuan Sheng, Aimin Zang, Zhang Zhanmin, Wenyan Chen, Xian Wang, Zhong Ouyang, Wěi Li, Barbara Pistilli, Thomas Bachelot, Mony Ung, Cristian Villanueva, Delphine Garbay, Anne-Claire Hardy-Bessard, Audrey Mailliez, Stéphanie Bécourt, William Mina, Thomas Decker, Julia Radosa, Andreas Schneeweiß, Michael Braun, Bahriye Aktas, Gábor Rubovszky, Zsuzsanna Pápai, Tibor Csőszi, Yousuf Al-Farhat, Ankit Patel, Vineet Govinda Gupta, Richu Sharma, Chandrakanth Mosale Venkatesha, Shailesh Bondarde, Somnath Roy, Nikhil Ghadyalpatil, Lalit Sen Sharma, Rajani Priya Yedla, Michelino De Laurentiis, Ida Paris and 101 more - Journal of Clinical Oncology 2024 cited by 140

  20. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Véronique Dièras, Hyo S. Han, Bella Kaufman, Hans Wildiers, Michael Friedländer, Jean-Pierre Ayoub, Shannon L. Puhalla, Igor Bondarenko, Mario Campone, Erik Jakobsen, Mathilde Jalving, Cristina Oprean, Markéta Palácová, Yeon Hee Park, Yaroslav Shparyk, Eduardo Yáñez, Nikhil Khandelwal, Madan G. Kundu, Matthew W. Dudley, Christine K. Ratajczak, David Maag, Banu Arun - The Lancet Oncology 2020 cited by 321

  21. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG)

    Authors: Laura Biganzoli, Nicolò Matteo Luca Battisti, Hans Wildiers, Amelia McCartney, Giuseppe Colloca, Ian Kunkler, Maria João Cardoso, Kwok‐Leung Cheung, N.A. de Glas, Rubina Manuela Trimboli, Beatriz Korc‐Grodzicki, Enrique Soto‐Pérez‐de‐Celis, Antonio Ponti, Janice Tsang, Lorenza Marotti, Karen Benn, Matti Aapro, Étienne Brain - The Lancet Oncology 2021 cited by 292

  22. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

    Authors: Nadia Harbeck, Eva Ciruelos, Guy Jérusalem, Volkmar Müller, Naoki Niikura, Giuseppe Viale, Rupert Bartsch, Christian Kurzeder, Michaela J. Higgins, Roisín M. Connolly, Sally Baron‐Hay, María Gión, Valentina Guarneri, Giampaolo Bianchini, Hans Wildiers, Santiago Escrivá-de-Romaní, Manoj Prahladan, Helen Bridge, Nataliya Kuptsova‐Clarkson, Nana Scotto, Sunil Verma, Nancy U. Lin, the DESTINY-Breast12 study group, Belinda Yeo, Nicole McCarthy, Amelia McCartney, Timothy Clay, Nicholas Murray, Andrea Gombos, Joëlle Collignon, Eveline De Cuypere, Katarzyna Jerzak, Stephen Chia, Maja Maraldo, Jeanette Rønlev, Eva Brix, Minna Tanner, Johanna Mattson, Riikka Huovinen, Pauline Wimberger, Mattea Reinisch, Hans Tesch, Michael Untch, Peter Fasching, Tjoung-Won Park-Simon, Joke Tio, Michael Braun, Eva Maria Grischke, Frederik Marmé, Marion van Mackelenbergh, John McCaffrey, Michelino De Laurentiis, Michele Caruso, Rossana Berardi, Laura Biganzoli, Vittoria Fotia, Toshinari Yamashita, Junji Tsurutani, Koichiro Tsugawa, Nobumoto Tomioka, Maaike de Boer, Daniel Houtsma, Martin Pilskog, Olav Engebråten, Anna Sætersdal, Piotr Wysocki, Zbigniew Nowecki, Barbara Radecka, Jacek Jassem, Renata Duchnowska, Joana Simões, Fatima Cardoso, Ana Rita Sousa, María Jesús Vidal Losada, Cristina Saura Manich, Joaquin Gavilá Gregori, Maria Pilar Lopez Marti, Manuel Ruiz Borrego, Javier Cortés Castán, Rafael López López, César Rodríguez Sanchez, Encarnación González Flores, Carmen Hinojo González, Purificación Martínez del Prado, Aglaia Schiza, Fredrika Killander, Leif Klint, Lorenzo Rossi, Stefan Aebi, Khalil Zaman, Peter Hall, Carey Anders - Nature Medicine 2024 cited by 183

  23. Geriatric assessment in the management of older patients with cancer – A systematic review (update)

    Authors: Marije E. Hamaker, Cecilia Margareta Lund, Marthe te Molder, Pierre Soubeyran, Hans Wildiers, Lieke van Huis, Siri Rostoft - Journal of Geriatric Oncology 2022 cited by 196

  24. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

    Authors: BOCS, Kyriaki Michailidou, kConFab Investigators, AOCS Group, NBCS, GENICA Network, Jonathan Beesley, Sara Lindström, Sander Canisius, Joe Dennis, Michael Lush, Mel Maranian, Manjeet K. Bolla, Qin Wang, Mitul Shah, Barbara Perkins, Kamila Czene, Mikael Eriksson, Hatef Darabi, Judith S. Brand, Stig E. Bojesen, Børge G. Nordestgaard, Henrik Flyger, Sune F. Nielsen, Nazneen Rahman, Clare Turnbull, Olivia Fletcher, Julian Peto, Lorna J. Gibson, Isabel dos‐Santos‐Silva, Jenny Chang‐Claude, Dieter Flesch‐Janys, Anja Rudolph, Ursula Eilber, Sabine Behrens, Heli Nevanlinna, Taru Muranen, Kristiina Aittomäki, Carl Blomqvist, Sofia Khan, Kirsimari Aaltonen, Habibul Ahsan, Muhammad G. Kibriya, Alice S. Whittemore, Esther M. John, Kathleen E. Malone, Marilie D. Gammon, Regina M. Santella, Giske Ursin, Enes Makalic, Daniel F. Schmidt, Graham Casey, David J. Hunter, Susan M. Gapstur, Mia M. Gaudet, W. Ryan Diver, Christopher A. Haiman, Fredrick R. Schumacher, Brian E. Henderson, Loı̈c Le Marchand, Christine D. Berg, Stephen J. Chanock, Jonine D. Figueroa, Robert N. Hoover, Diether Lambrechts, Patrick Neven, Hans Wildiers, Erik Van Limbergen, Marjanka K. Schmidt, Annegien Broeks, Senno Verhoef, Sten Cornelissen, Fergus J. Couch, Janet E. Olson, Emily Hallberg, Celine M. Vachon, Quinten Waisfisz, Hanne Meijers‐Heijboer, Muriel A. Adank, Rob B. van der Luijt, Jingmei Li, Jianjun Liu, Keith Humphreys, Daehee Kang, Ji‐Yeob Choi, Sue K. Park, Keun-Young Yoo, Keitaro Matsuo, Hidemi Ito, Hiroji Iwata, Kazuo Tajima, Pascal Guénel, Thérèse Truong, Claire Mulot, Marie Sanchez, Barbara Burwinkel, Frederik Marmé, Harald Surowy, Christof Sohn, Anna H. Wu and 148 more - Nature Genetics 2015 cited by 634